Ariel Hammerman
Ariel Hammerman
Director of Pharmaceutical Technology Assessment Dept., Clalit Health Services Headquarters, Tel-Aviv, Israel
Verified email at
Cited by
Cited by
Economic implications of 21‐gene breast cancer risk assay from the perspective of an Israeli‐managed health‐care organization
SH Klang, A Hammerman, N Liebermann, N Efrat, J Doberne, ...
Value in Health 13 (4), 381-387, 2010
Antipsychotics and diabetes: an age-related association
A Hammerman, J Dreiher, SH Klang, H Munitz, AD Cohen, M Goldfracht
Annals of Pharmacotherapy 42 (9), 1316-1322, 2008
Systemic therapy for psoriasis and the risk of herpes zoster: a 500 000 person-year study
G Shalom, D Zisman, H Bitterman, I Harman-Boehm, S Greenberg-Dotan, ...
JAMA dermatology 151 (5), 533-538, 2015
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data
E Dudnik, M Moskovitz, S Daher, S Shamai, E Hanovich, A Grubstein, ...
Lung cancer 126, 217-223, 2018
Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation
R Arbel, R Sergienko, A Hammerman, S Greenberg-Dotan, E Batat, ...
The American journal of medicine 132 (7), 847-855. e3, 2019
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study
MH Ellis, T Neuman, H Bitterman, SG Dotan, A Hammerman, E Battat, ...
European journal of internal medicine 33, 55-59, 2016
Variability in outpatient antimicrobial consumption in Israel
O Nitzan, M Low, I Lavi, A Hammerman, S Klang, R Raz
Infection 38 (1), 12-18, 2010
Trends in outpatient antibiotic use in Israel during the years 2000–2010: setting targets for an intervention
M Low, O Nitzan, H Bitterman, C Cohen, A Hammerman, N Lieberman, ...
Infection 41 (2), 401-407, 2013
Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis
DA Goldstein, Q Chen, T Ayer, KKW Chan, K Virik, A Hammerman, ...
The oncologist 22 (6), 694, 2017
PCSK9 inhibitors may improve cardiovascular outcomes—Can we afford them?
R Arbel, A Hammerman, N Triki, D Greenberg
International journal of cardiology 220, 242-245, 2016
Estimating the budget impact of new technologies added to the national list of health services in Israel: stakeholders’ incentives for adopting a financial risk-sharing mechanism
A Hammerman, D Greenberg
Health policy 89 (1), 78-83, 2009
The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel
A Hammerman, S Greenberg-Dotan, I Feldhamer, Y Birnbaum, NI Cherny
Expert review of pharmacoeconomics & outcomes research 18 (1), 119-122, 2018
Which is more valuable, longer survival or better quality of life? Israeli oncologists’ and family physicians’ attitudes toward the relative value of new cancer and congestive …
D Greenberg, A Hammerman, S Vinker, A Shani, Y Yermiahu, ...
Value in health 16 (5), 842-847, 2013
The ‘real-life’impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study
A Hammerman, S Greenberg-Dotan, E Battat, I Feldhamer, H Bitterman, ...
Acta Oncologica 54 (2), 164-170, 2015
Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach
A Gavious, D Greenberg, A Hammerman, E Segev
The European Journal of Health Economics 15 (5), 553-561, 2014
A prospective study of the impact of the 21-gene recurrence score assay on treatment decisions in N-, ER+ early stage breast cancer patients
N Ben-Baruch, A Hammerman, S Klang, N Liebermann
Journal of Clinical Oncology 25 (18_suppl), 11008-11008, 2007
Israel Lung Cancer Group. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
E Dudnik, M Moskovitz, S Daher, S Shamai, E Hanovich, A Grubstein, ...
Lung Cancer 126, 217-223, 2018
Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study
M Leventer-Roberts, A Hammerman, I Brufman, M Hoshen, M Braun, ...
Plos one 12 (7), e0176858, 2017
Oncologists’ and family physicians’ views on value for money of cancer and congestive heart failure care
D Greenberg, A Hammerman, S Vinker, A Shani, Y Yermiahu, ...
Israel journal of health policy research 2 (1), 1-10, 2013
Financial Risk-Sharing in Updating the National List of Health Services in Israel: Stakeholders' Perceived Interests
A Hammerman, P Feder-Bubis, D Greenberg
Value in Health 15 (5), 737-742, 2012
The system can't perform the operation now. Try again later.
Articles 1–20